Your browser doesn't support javascript.
loading
Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma.
Makino, Hirofumi; Notsu, Masakazu; Asayama, Itsuko; Otani, Hazuki; Morita, Miwa; Yamamoto, Masahiro; Yamauchi, Mika; Nakao, Mika; Miyake, Hitomi; Araki, Asuka; Uchino, Shinya; Kanasaki, Keizo.
Afiliação
  • Makino H; Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
  • Notsu M; Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
  • Asayama I; Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
  • Otani H; Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
  • Morita M; Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
  • Yamamoto M; Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
  • Yamauchi M; Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
  • Nakao M; Research Institute for Metabolic Bone Diseases, Eikokai Ono Hospital, Japan.
  • Miyake H; Cancer Genome Medical Center, Shimane University Faculty of Medicine, Japan.
  • Araki A; Department of Internal Medicine, Unnan City Hospital, Japan.
  • Uchino S; Organ Pathology Unit, Department of Pathology, Shimane University Faculty of Medicine, Japan.
  • Kanasaki K; Noguchi Thyroid Clinic and Hospital Foundation, Japan.
Intern Med ; 61(22): 3383-3390, 2022 Nov 15.
Article em En | MEDLINE | ID: mdl-35370235
ABSTRACT
Parathyroid carcinoma (PC) is a rare type of endocrine cancer. Recurrence and metastasis are common after surgery, and refractory hypercalcemia often leads to a poor prognosis. However, there are currently no specific strategies for PC recurrence. We herein report a 61-year-old Japanese man with metastatic PC who was treated with sorafenib, a multikinase inhibitor. In this case, the serum calcium level was under control for 10 months after the initiation of sorafenib. This case suggests that combination therapy with sorafenib, evocalcet, and denosumab may be an alternative, stronger management option for refractory hypercalcemia in recurrent PC.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Assunto principal: Neoplasias das Paratireoides / Hipercalcemia Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Revista: Intern Med Assunto da revista: MEDICINA INTERNA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Assunto principal: Neoplasias das Paratireoides / Hipercalcemia Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Revista: Intern Med Assunto da revista: MEDICINA INTERNA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão